{
    "clinical_study": {
        "@rank": "65518", 
        "arm_group": [
            {
                "arm_group_label": "small dose", 
                "arm_group_type": "Experimental", 
                "description": "10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg\u00b7h) infusion until the end of surgery"
            }, 
            {
                "arm_group_label": "medium dose", 
                "arm_group_type": "Experimental", 
                "description": "20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg\u00b7h) infusion until the end of surgery"
            }, 
            {
                "arm_group_label": "large dose", 
                "arm_group_type": "Experimental", 
                "description": "30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg\u00b7h) infusion until the end of surgery"
            }
        ], 
        "brief_summary": {
            "textblock": "Tranexamic acid, an antifibrinolytic drug, is wildly used in cardiac surgeries to decrease\n      perioperative bleeding and allogenic transfusion. But the optimum dose of tranexamic acid is\n      still unknown. We use three different doses to find which is the optimum dose of tranexamic\n      acid in cardiopulmonary bypass cardiac surgery."
        }, 
        "brief_title": "Prospective Trial of Tranexamic Acid in Cardiac Surgery", 
        "condition": "C.Surgical Procedure; Cardiac", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Noncyanotic congenital heart disease patients requiring cardiac surgeries under\n             cardiopulmonary bypass\n\n          -  Rheumatic or recessive valvular disease patients requiring valvular repair or\n             replacement under cardiopulmonary bypass\n\n          -  Coronary artery disease patients requiring coronary artery bypass graft under\n             cardiopulmonary bypass\n\n        Exclusion Criteria:\n\n          -  Non-primary and emergency cardiac surgery\n\n          -  Disorder in coagulation function before surgery\n\n          -  Anemia before surgery\n\n          -  Definite liver and renal dysfunction\n\n          -  History of stroke\n\n          -  Pregnancy and lactation\n\n          -  Disabled in spirit or law\n\n          -  Fatal conditions such as cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "810", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998438", 
            "org_study_id": "2011GWH1"
        }, 
        "intervention": {
            "arm_group_label": [
                "small dose", 
                "medium dose", 
                "large dose"
            ], 
            "intervention_name": "Tranexamic Acid", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tranexamic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "tranexamic acid", 
            "cardiac surgery", 
            "cardiopulmonary bypass"
        ], 
        "lastchanged_date": "November 24, 2013", 
        "location": {
            "contact": {
                "email": "jihongwen@hotmail.com", 
                "last_name": "Hongwen Ji, MD", 
                "phone": "86-10-88398185"
            }, 
            "contact_backup": {
                "email": "luhaisong@aliyun.com", 
                "last_name": "Haisong Lu", 
                "phone": "86-10-88398082"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100037"
                }, 
                "name": "Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC"
            }, 
            "investigator": {
                "last_name": "Haisong Lu", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Double-blinded Trial to Explore the Optimum Dose of Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery", 
        "other_outcome": {
            "measure": "rate of reexploration for bleeding", 
            "safety_issue": "Yes", 
            "time_frame": "on the 7th day postoperatively"
        }, 
        "overall_contact": {
            "email": "jihongwen@hotmail.com", 
            "last_name": "Hongwen Ji, MD", 
            "phone": "86-10-88398185"
        }, 
        "overall_contact_backup": {
            "email": "luhaisong@aliyun.com", 
            "last_name": "Haisong Lu", 
            "phone": "86-10-88398082"
        }, 
        "overall_official": [
            {
                "affiliation": "Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC", 
                "last_name": "Hongwen Ji, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC", 
                "last_name": "Haisong Lu", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "postoperative blood loss", 
            "safety_issue": "Yes", 
            "time_frame": "on the 7th day postoperatively"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998438"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union M", 
            "investigator_full_name": "Hongwen Ji", 
            "investigator_title": "professor of medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "number of participants needs allogenic transfusion", 
            "safety_issue": "Yes", 
            "time_frame": "on the 7th day postoperatively"
        }, 
        "source": "Cardiovascular Institute & Fuwai Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hongwen Ji", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}